

Lead optimization of Tau-ATTEC as a therapeutic agent for progressive supranuclear palsy

Korea Research Institute of Chemical Technology



NEUROLOGY	Lead
Product Type	Targeted Protein Degradation
Indication	Progressive supranuclear palsy
Target	Tau aggregates
MoA(Mechanism of Action)	Autophagy lysosomal degradation of tau aggregates
Competitiveness	- Disease modifying drug for progressive supranuclear palsy - Exhibiting Tau/p-Tau degradation and also tau aggregation inhibition
Development Stage	Lead
Route of Administration	P.O.

Any unauthorized distribution or reproduction of this material is strictly prohibited.